NCT00278460已完成2 期
A Phase II Study of Taxotere and Gemcitabine for Stages III-B and IV Non-Small Cell Lung Cancer
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 49
- 主要终点
- patient response rate to weekly taxotere and gemcitabine
研究概览
简要总结
RATIONALE: Drugs used in chemotherapy, such as gemcitabine and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells.
PURPOSE: This phase II trial is studying how well giving gemcitabine together with docetaxel works in treating patients with recurrent stage III or stage IV non-small cell lung cancer.
详细描述
OBJECTIVES:
Primary
- Determine the response rate of patients with recurrent stage IIIB and IV non-small cell lung cancer treated with gemcitabine hydrochloride and docetaxel.
- Determine the overall and progression-free survival of patients treated with this regimen.
- Determine the toxic effects of this regimen in these patients.
Secondary
- Determine the duration of response in patients treated with this regimen.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 120 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •DISEASE CHARACTERISTICS:
- •Histologically confirmed stage IIIB or IV non-small cell lung cancer, including any of the following types:
- •Squamous cell carcinoma
- •Adenocarcinoma, including bronchoalveolar cell adenocarcinoma
- •Large cell anaplastic carcinoma, including giant and clear cell carcinomas
- •Histologic or cytologic documentation of recurrence is required
- •Measurable or evaluable disease, defined as any mass reproducibly measurable in 2 perpendicular diameters by physical examination or imaging
- •The following lesions are not considered measurable or evaluable:
- •Bone disease only
- •Pleural or pericardial effusions
- •Previously irradiated lesions, unless subsequent progression is documented
- •CNS metastases allowed provided the patient undergoes at least 2 weeks of radiotherapy prior to study entry
- •PATIENT CHARACTERISTICS:
- •Not pregnant or nursing
- •Fertile patients must use effective contraception
- •Negative pregnancy test
- •CALGB performance status ≤ 1
- •Life expectancy ≥ 3 months
- •Granulocyte count > 1,500/mm^3
- •Platelet count ≥ 100,000/mm^3
- •Creatinine ≤ 2 times normal
- •Bilirubin normal
- •SGOT and/or SGPT ≤ 2.5 times upper limit of normal (ULN) AND alkaline phosphatase ≤ 1.5 times ULN OR
- •Alkaline phosphatase 4 times ULN and SGOT and/or SGPT normal
- •Ejection fraction normal by ECHO or MUGA
- •No history of congestive heart failure
- •No psychiatric illness that would preclude study compliance
- •No serious medical or psychiatric illness that would preclude giving informed consent or limit survival to < 3 months
- •No active uncontrolled bacterial, fungal, or viral infection
- •No other malignancy within the past 5 years except curatively treated carcinoma in situ of the cervix or breast, basal cell or squamous carcinoma of the skin, or other surgically resected non-recurrent primary tumor not treated with adjuvant radiotherapy or chemotherapy
- •No pre-existing peripheral neuropathy ≥ grade 2
- •PRIOR CONCURRENT THERAPY:
- •At least 2 weeks since prior major surgery and recovered from acute effects
- •At least 2 weeks since prior palliative radiotherapy and recovered from acute toxic effects
- •Any persistent toxicity (e.g., alopecia or hyperpigmentation) not associated with clinical morbidity allowed
- •No prior chemotherapy
- •No concurrent cranial or thoracic radiation therapy
- •No concurrent cytotoxic or hormonal therapy
- •Concurrent palliative radiotherapy allowed for relief of localized pain and obstruction
排除标准
- 未提供
结局指标
主要结局
patient response rate to weekly taxotere and gemcitabine
时间窗: 6 weeks
次要结局
- Evaluate toxicity of weekly Taxotere and Gemcitabine(6 weeks)
研究者
相似试验
已完成
2 期
Gemcitabine and Docetaxel in Treating Patients With Metastatic Prostate CancerProstate CancerNCT00276549Case Comprehensive Cancer Center35
已完成
2 期
Gemcitabine and Docetaxel in Treating Patients With Persistent, Recurrent, or Metastatic Head and Neck CancerHead and Neck CancerNCT00248560Barbara Ann Karmanos Cancer Institute36
已完成
2 期
Gemcitabine and Docetaxel in Treating Patients With Relapsed or Refractory Ovarian Epithelial or Peritoneal CancerPeritoneal Cavity CancerOvarian CancerNCT00227721Robert Morris30
已完成
2 期
Gemcitabine and Docetaxel in Treating Patients With Recurrent Osteosarcoma (Closed to Accrual as of 12/21/06) or Ewing's Sarcoma or Unresectable or Locally Recurrent ChondrosarcomaSarcomaNCT00073983Sarcoma Alliance for Research through Collaboration54
已完成
2 期
Gemcitabine With or Without Docetaxel as Second-Line Therapy in Treating Patients With Metastatic or Relapsed, Unresectable Uterine or Soft Tissue LeiomyosarcomaSarcomaNCT00227669UNICANCER90